translation agency

PR Newswire
Immunization With REMUNE(R) in Immunocompetent HIV-Infected Patients May Lead To Stronger Immune Responses and Possible Control of Viral Replication

May 13, 2002
CARLSBAD, Calif., May 13 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today publication of data suggesting that immune responses to therapeutic immunization with REMUNE(R) were more optimal in HIV infected patients with high CD4 cell counts and low virus levels. The article "Predictors of HIV Specific Lymphocyte Proliferative Immune Responses Induced by Therapeutic Vaccination" appears in the May issue of Clinical and Experimental Immunology (128:359-364).

The open label study of 38 HIV infected individuals determined whether baseline parameters such as CD4 cell counts and the amount of virus in the blood were predictive of the magnitude of the HIV specific lymphocyte proliferative response to REMUNE(R). Lymphocyte proliferative responses to HIV antigens appeared to be significantly enhanced after immunization (P<0.0001). Low viral load (r = -0.482, p = 0.003) and high CD4 cell counts (r = 0.368, p = 0.03) prior to immunization appeared significantly associated with better lymphocyte proliferative responses when measured at week 28 after immunization with REMUNE(R). In addition, low levels of IgG, a measurement of immune activation, appeared associated with better immune responses after vaccination (r = -0.369, p = 0.02).

The authors concluded, "vaccination in a more optimal cohort (high CD4 cell counts, low viral load, low immune activation) may lead to stronger immune responses and possible control of viral replication. Thus testing of this and other immune-based therapies in early disease, or as drug sparing adjuvants in subjects with high CD4 cell counts and low viral load, becomes particularly relevant." The article can be found at http://www.blackwell- 046/j.1365-2249.2002.01835.x

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company has developed and patented a novel technology to be applied to any gene in order to increase expression of that gene. NOTE: Company information can also be located on the Internet Web Site:

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether data generated from previous trials can be replicated in future clinical trials, whether clinical trials will be successfully concluded, whether REMUNE(R) will be approved for marketing or be successfully commercialized and whether the Company will be able to obtain additional financing. Those factors are discussed more thoroughly in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation.